Product Information
SUMATRIPTAN SUCC 100 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.4388 per EA under NDC 00378563259. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Aug 10, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378563259
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SUMATRIPTAN SUCCINATEApproval Type
Generic (ANDA)
FDA Application
ANDA077744FDA Approved
8/10/2009
TE Code
AB
On Market Since
8/10/2009
Pharmacological Classes
Price Statistics
The NADAC for SUMATRIPTAN SUCC 100 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 53.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4388 per EA |
|---|---|
| All-time high | $1.0526 (Mar 11, 2015) |
| All-time low | $0.3720 (Nov 20, 2024) |
| 52-week high | $0.4721 |
| 52-week low | $0.4309 |
| Median price | $0.5836 |
| Average price | $0.6221 |
| Largest weekly change | -23.3% (Nov 20, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sumatriptan succinate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUMATRIPTAN SUCC 100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SUMATRIPTAN SUCC 100 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $0.4388 per EA (NDC 00378563259), effective Sep 30, 2026.
How has the price of SUMATRIPTAN SUCC 100 MG TABLET changed over time?
Over the history we have for it, the NADAC for SUMATRIPTAN SUCC 100 MG TABLET has declined 53.2%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for SUMATRIPTAN SUCC 100 MG TABLET?
Since Nov 28, 2013, the NADAC for SUMATRIPTAN SUCC 100 MG TABLET has ranged from a low of $0.3720 (Nov 20, 2024) to a high of $1.0526 (Mar 11, 2015), with a median of $0.5836 per EA.
Are there cheaper alternatives to SUMATRIPTAN SUCC 100 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SUMATRIPTAN SUCC 100 MG TABLET, is $0.4309 per EA — about 2% below SUMATRIPTAN SUCC 100 MG TABLET.
Who manufactures SUMATRIPTAN SUCC 100 MG TABLET?
SUMATRIPTAN SUCC 100 MG TABLET (NDC 00378563259) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.